Respiratory syncytial virus infectious disease
diseaseOn this page
Also known as Human respiratory syncytial virus infectioninfections, Human respiratory syncytial virusrespiratory syncytial virus infection
Summary
Respiratory syncytial virus infectious disease (MONDO:0001577) is a disease and 208 clinical trials. Top therapeutic interventions include nirsevimab, palivizumab, and respiratory syncytial virus pre-fusion glycoprotein f. A subtype of Mononegavirales infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 208
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | respiratory syncytial virus infectious disease |
| Mondo ID | MONDO:0001577 |
| EFO | EFO:1001413 |
| MeSH | D018357 |
| DOID | DOID:1273 |
| NCIT | C3354 |
| SNOMED CT | 55735004 |
| UMLS | C0035235 |
| MedGen | 48424 |
| Is cancer (heuristic) | no |
Also known as: Human respiratory syncytial virus infection · infections, Human respiratory syncytial virus · respiratory syncytial virus infection
Disease family
An umbrella term covering 1 Mondo subtype.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Mononegavirales infectious disease › respiratory syncytial virus infectious disease
Related subtypes (4): Filoviridae infectious disease, Paramyxoviridae infectious disease, Rhabdoviridae infectious disease, borna virus encephalitis
Subtypes (1): respiratory syncytial virus bronchiolitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
4 approved, 9 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Nirsevimab | Approved (phase 4) |
| Palivizumab | Approved (phase 4) |
| Respiratory Syncytial Virus Pre-Fusion Glycoprotein F | Approved (phase 4) |
| Respiratory Syncytial Virus Pre-Fusion Glycoprotein F Mrna | Approved (phase 4) |
| AD26.RSV.PREF | Phase 3 (in late-stage trials) |
| Clesrovimab | Phase 3 (in late-stage trials) |
| Elasomeran | Phase 3 (in late-stage trials) |
| Influenza Virus Vaccine | Phase 3 (in late-stage trials) |
| Motavizumab | Phase 3 (in late-stage trials) |
| Ribavirin | Phase 3 (in late-stage trials) |
| Sodium Chloride | Phase 3 (in late-stage trials) |
| Suptavumab | Phase 3 (in late-stage trials) |
| Ziresovir | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Azithromycin, MATRIX-M1 ADJUVANT, Molnupiravir, Rilematovir.
Clinical trials & evidence
Clinical trials
Clinical trials: 208.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 61 |
| Not specified | 48 |
| PHASE2 | 43 |
| PHASE3 | 35 |
| PHASE1/PHASE2 | 14 |
| PHASE2/PHASE3 | 5 |
| PHASE4 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00001903 | PHASE4 | COMPLETED | Prevention of RSV Infections in Bone Marrow Transplant Recipients |
| NCT06551506 | PHASE4 | COMPLETED | The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products |
| NCT04732871 | PHASE3 | ACTIVE_NOT_RECRUITING | Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above |
| NCT05026749 | PHASE3 | RECRUITING | Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children |
| NCT06363370 | PHASE3 | RECRUITING | Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections |
| NCT06534892 | PHASE3 | ACTIVE_NOT_RECRUITING | An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study |
| NCT06593210 | PHASE3 | ACTIVE_NOT_RECRUITING | RSV Vaccine in Transplant Recipients |
| NCT07220109 | PHASE3 | RECRUITING | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease |
| NCT07402512 | PHASE3 | RECRUITING | A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children |
| NCT00031473 | PHASE3 | TERMINATED | Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients |
| NCT00129766 | PHASE3 | COMPLETED | Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
| NCT01006629 | PHASE2/PHASE3 | COMPLETED | Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children |
| NCT01466062 | PHASE3 | COMPLETED | Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions |
| NCT02325791 | PHASE3 | COMPLETED | Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants |
| NCT02624947 | PHASE3 | COMPLETED | A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization |
| NCT03959488 | PHASE2/PHASE3 | COMPLETED | A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children |
| NCT03979313 | PHASE3 | COMPLETED | A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) |
| NCT04231968 | PHASE3 | COMPLETED | A Study of AK0529 in Chinese Infants Hospitalized With RSV |
| NCT04605159 | PHASE3 | TERMINATED | A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers |
| NCT04767373 | PHASE2/PHASE3 | COMPLETED | Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) |
| NCT04841577 | PHASE3 | COMPLETED | A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above |
| NCT04886596 | PHASE3 | COMPLETED | Efficacy Study of GSK’s Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above |
| NCT04980391 | PHASE3 | TERMINATED | A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers |
| NCT05045144 | PHASE3 | COMPLETED | A Phase III Study to Assess the Lot-to-lot Consistency of GSK’s Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK’s Influenza D-QIV Vaccine in Healthy Non-pregnant Women. |
| NCT05059301 | PHASE3 | COMPLETED | A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above |
| NCT05169905 | PHASE3 | COMPLETED | A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age |
| NCT05229068 | PHASE3 | WITHDRAWN | A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy |
| NCT05238025 | PHASE3 | TERMINATED | MVA-BN-RSV Vaccine Trial |
| NCT05559476 | PHASE3 | COMPLETED | A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above |
| NCT05568797 | PHASE3 | COMPLETED | A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above |
| NCT05590403 | PHASE3 | COMPLETED | A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above |
| NCT05705440 | PHASE3 | COMPLETED | A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control |
| NCT05879107 | PHASE3 | COMPLETED | Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults |
| NCT05966090 | PHASE3 | COMPLETED | A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults |
| NCT06042049 | PHASE3 | COMPLETED | A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab |
| NCT06079320 | PHASE2/PHASE3 | TERMINATED | A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection |
| NCT06083623 | PHASE2/PHASE3 | COMPLETED | A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants |
| NCT06374394 | PHASE3 | COMPLETED | A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above |
| NCT06389487 | PHASE3 | COMPLETED | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above |
| NCT06551181 | PHASE3 | COMPLETED | A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| NIRSEVIMAB | 4 | 6 |
| PALIVIZUMAB | 4 | 5 |
| RESPIRATORY SYNCYTIAL VIRUS PRE-FUSION GLYCOPROTEIN F | 4 | 2 |
| PENTETIC ACID | 4 | 1 |
| REMDESIVIR | 4 | 1 |
| TECHNETIUM TC 99M PENTETATE | 4 | 1 |
| VERAPAMIL | 4 | 1 |
| RILEMATOVIR | 3 | 5 |
| ZIRESOVIR | 3 | 5 |
| MOTAVIZUMAB | 3 | 4 |
| CLESROVIMAB | 3 | 1 |
| REPROXALAP | 3 | 1 |
| SUPTAVUMAB | 3 | 1 |
| LUMICITABINE | 2 | 8 |
| SISUNATOVIR | 2 | 6 |
| PRESATOVIR | 2 | 4 |
| ASVASIRAN SODIUM | 2 | 3 |
| ALX-0171 | 2 | 2 |
| PC-786 | 2 | 2 |
| DEXVERAPAMIL | 2 | 1 |
| JNJ-49095397 | 2 | 1 |
| RSV-604 | 2 | 1 |
| ZELICAPAVIR | 2 | 1 |
| BTA-9881 | 1 | 1 |
| VP-14637 | 1 | 1 |
| CHEMBL443232 | 0 | 3 |
| CHEMBL4748591 | 0 | 2 |
| CHEMBL4061258 | 0 | 1 |
| CHEMBL5094495 | 0 | 1 |
| CHEMBL5280654 | 0 | 1 |